IPO - Inmune Bio, Inc.

Form Type: 424B5

Filing Date: 2025-06-30

Corporate Action: Ipo

Type: New

Accession Number: 000121390025059298

Filing Summary: On June 30, 2025, Inmune Bio, Inc. filed a prospectus supplement offering 3,000,000 shares of its common stock at an offering price of $6.30 per share, targeting two healthcare-focused institutional investors. As of June 26, 2025, the last sale price of the stock was noted at $6.28. The offering is part of a shelf registration that allows for up to $250 million in sales of securities. The estimated net proceeds from the offering are projected to be approximately $17.4 million after deducting fees, which will be utilized for general corporate purposes and working capital. The placement agent for this offering is A.G.P./Alliance Global Partners, which receives a 7% fee from gross proceeds. The company highlights its focus on the development of treatments for cancer and neurological conditions, with significant updates on trials for its products, including XPro for Alzheimer’s Disease and treatment-resistant depression, and CORDStrom for rare skin diseases. The document stresses the associated risks of investing in the securities, including high degrees of potential dilution and the discretion in utilizing proceeds.